MedPath

A Single Dose Study to Evaluate the Pharmacokinetics and Glucodynamics of insulin peglispro (LY2605541) in Healthy Male Japanese Subjects

Phase 1
Conditions
Healthy Volunteer
Registration Number
JPRN-jRCT2080222319
Lead Sponsor
Eli Lilly Japan K.K.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
Male
Target Recruitment
Not specified
Inclusion Criteria

Participants are overtly healthy male Japanese.
Participants have Body Mass Index (BMI) between 18.5 and 25.0 kilogram per square meter (kg/m^2), inclusive.

Exclusion Criteria

Participants have known allergies to insulin peglispro, related compounds.
Participants have a fasting venous blood glucose >108 milligram per deciliter (mg/dL) (>6 millimole per liter [mmol/L]).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath